Inhibition of c-Src blocks oestrogen-induced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells

European Journal of Cancer

Volumn 50, Issue 2, 2014, Pages 457-468

  Fan, Ping ^a   Agboke, Fadeke A ^a   McDaniel, Russell E ^a   Sweeney, Elizabeth E ^a   Zou, Xiaojun ^a   Creswell, Karen ^a   Jordan, V Craig ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Apoptosis; Breast cancer; c Src; Epithelial mesenchymal transition; Oestrogen

Indexed keywords

4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; ESTRADIOL; ESTROGEN; FULVESTRANT; INSULIN LIKE GROWTH FACTOR 1 RECEPTOR BETA; MESSENGER RNA; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST1; UNCLASSIFIED DRUG; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FLOW CYTOMETRY; GENE REPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

EID: 84891828889     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.10.001     Document Type: Article

References (40)

1. V.C. Jordan, and A.M. Brodie Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer Steroids 72 2007 7 25
2. M. Dowsett, J. Cuzick, and J. Ingle et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 2010 509 518
3. E.E. Sweeney, R.E. McDaniel, P.Y. Maximov, P. Fan, and V.C. Jordan Models and mechanisms of acquired antihormone resistance in breast cancer: significant clinical progress despite limitations Horm Mol Biol Clin Investig 9 2012 143 163
4. M.M. Gottardis, S.Y. Jiang, M.H. Jeng, and V.C. Jordan Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens Cancer Res 49 1989 4090 4093
5. E.A. Ariazi, J.S. Lewis-Wambi, and S.D. Gill et al. Emerging principles for the development of resistance to antihormonal therapy: implications for the clinical utility of fulvestrant J Steroid Biochem Mol Biol 102 2006 128 138
6. M.M. Gottardis, and V.C. Jordan Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration Cancer Res 48 1988 5183 5187
7. D.M. Wolf, and V.C. Jordan A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy Recent Results Cancer Res 127 1993 23 33
8. K. Yao, E.S. Lee, and D.J. Bentrem et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice Clin Cancer Res 6 2000 2028 2036
9. J.S. Lewis-Wambi, and V.C. Jordan Estrogen regulation of apoptosis: how can one hormone stimulate and inhibit? Breast Cancer Res 11 2009 206
10. G.L. Anderson, R.T. Chlebowski, and A.K. Aragaki et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial Lancet Oncol 13 2012 476 486
11. I. Obiorah, and V.C. Jordan The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortality Menopause 20 2013 372 382
12. C. Davies, H. Pan, and J. Godwin et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial Lancet 381 2013 805 816
13. C. Osipo, C. Gajdos, H. Liu, B. Chen, and V.C. Jordan Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer J Natl Cancer Inst 95 2003 1597 1608
14. R.X. Song, G. Mor, and F. Naftolin et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17 beta-estradiol J Natl Cancer Inst 93 2001 1714 1723
15. J.S. Lewis, K. Meeke, and C. Osipo et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation J Natl Cancer Inst 97 2005 1746 1759
16. H. Liu, E.S. Lee, and C. Gajdos et al. Apoptotic action of 17beta-estradiol in raloxifene-resistant MCF-7 cells in vitro and in vivo J Natl Cancer Inst 95 2003 1586 1597
17. M.J. Ellis, F. Gao, and F. Dehdashti et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study JAMA 302 2009 774 780
18. E.A. Ariazi, H.E. Cunliffe, and J.S. Lewis-Wambi et al. Estrogen induces apoptosis in estrogen deprivation-resistant breast cancer through stress responses as identified by global gene expression across time Proc Natl Acad Sci U S A 108 2011 18879 18886
19. P. Fan, O.L. Griffith, and F. Agboke et al. C-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells Cancer Res 73 2013 4510 4520
20. P. Fan, R.E. McDaniel, H.R. Kim, D. Clagett, B. Haddad, and V.C. Jordan Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines Eur J Cancer 48 2012 3488 3498
21. S. Hiscox, L. Morgan, T.P. Green, D. Barrow, J. Gee, and R.I. Nicholson Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Res Treat 97 2006 263 274
22. P. Fan, J. Wang, R.J. Santen, and W. Yue Long-term treatment with tamoxifen facilitates translocation of estrogen receptor alpha out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells Cancer Res 67 2007 1352 1360
23. Y. Chen, N. Guggisberg, and M. Jorda et al. Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors Clin Cancer Res 15 2009 3396 3405
24. S. Hiscox, N.J. Jordan, and C. Smith et al. Dual targeting of SRC and ER prevents acquired antihormone resistance in breast cancer cells Breast Cancer Res Treat 115 2009 57 67
25. S. Sengupta, R. Schiff, and B.S. Katzenellenbogen Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells Breast Cancer Res Treat 117 2009 243 251
26. C.A. Lange, T. Shen, and K.B. Horwitz Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome Proc Natl Acad Sci U S A 97 2000 1032 1037
27. M.H. Jeng, S.M. Langan-Fahey, and V.C. Jordan Estrogenic actions of RU486 in hormone-responsive MCF-7 human breast cancer cells Endocrinology 132 1993 2622 2630
28. P.A. Bromann, H. Korkaya, and S.A. Courtneidge The interplay between Src family kinases and receptor tyrosine kinases Oncogene 23 2004 7957 7968
29. J.S. Nam, Y. Ino, M. Sakamoto, and S. Hirohashi Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis Clin Cancer Res 8 2002 2430 2436
30. A. Moustakas, and C.H. Heldin Signaling networks guiding epithelial-mesenchymal transitions during embryogenesis and cancer progression Cancer Sci 98 2007 1512 1520
31. J.H. Taube, J.I. Herschkowitz, and K. Komurov et al. Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes Proc Natl Acad Sci U S A 107 2010 15449 15454
32. M. Genua, G. Pandini, and D. Sisci et al. Role of cyclic AMP response element-binding protein in insulin-like growth factor-1 receptor up-regulation by sex steroids in prostate cancer cells Cancer Res 69 2009 7270 7277
33. C. Hernández-Sánchez, V. Blakesley, T. Kalebic, L. Helman, and D. LeRoith The role of the tyrosine kinase domain of the insulin-like growth factor-I receptor in intracellular signaling, cellular proliferation, and tumorigenesis J Biol Chem 270 1995 29176 29181
34. M.J. Martin, N. Melnyk, and M. Pollard et al. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase Mol Cell Biol 26 2006 1754 1769
35. S. Holmstrom, M.E. Van Antwerp, and J.A. Iniguez-Lluhi Direct and distinguishable inhibitory roles for SUMO isoforms in the control of transcriptional synergy Proc Natl Acad Sci U S A 100 2003 15758 15763
36. E. Avizienyte, A.W. Wyke, and R.J. Jones et al. Src-induced de-regulation of E-cadherin in colon cancer cells requires integrin signaling Nat Cell Biol 4 2002 632 638
37. E.M. Balzer, R.A. Whipple, and K. Thompson et al. C-Src differentially regulates the functions of microtentacles and invadopodia Oncogene 29 2010 6402 6408
38. B.J. Rybarczyk, and P.J. Simpson-Haidaris Fibrinogen assembly, secretion, and deposition into extracellular matrix by MCF-7 human breast carcinoma cells Cancer Res 60 2000 2033 2039
39. T.T. Onder, P.B. Gupta, S.A. Mani, J. Yang, E.S. Lander, and R.A. Weinberg Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways Cancer Res 68 2008 3645 3654
40. C.W. Li, W. Xia, and L. Huo et al. Epithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1 Cancer Res 72 2012 1290 1300